THAR Projected Dividend Yield
Com (Par)/Tharimmune Inc ( NASDAQ : THAR )Tharimmune, Inc. is a clinical-stage biotechnology company. Co. is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. 21 YEAR PERFORMANCE RESULTS |
THAR Dividend History Detail THAR Dividend News THAR Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |